On this page:

• Adverse Events Following Immunization
• COVID-19 Immunization Documents
• Provincial Guidance
• Infection Prevention and Control
• Health Canada
• National Advisory Committee on Immunization
• Public Health Agency of Canada
• Vaccine Product Information
• Pharmacist Guidance
• Physician Guidance

Adverse Events Following Immunization

• All Adverse Events Following Immunization (AEFIs) are to be reported to the Regional Medical Officer of Health. For details, please refer to the Newfoundland and Labrador Immunization Manual.
• Report of AEFI Form

COVID-19 Immunization Documents 

• After Care and Immunization Record
• After Care and Immunization Record for Students
• Consent Form
  • Fillable PDF form (note: you can view the fillable PDF form using Internet Explorer. If you are using another browser, you can download the file and view it in Adobe Reader)
• School Consent Form – note: this is a fillable PDF form. You can view the form using Internet Explorer. If you are using another browser, you can download the file and view it in Adobe Reader.
• School Consent Form Student Record – note: this is a fillable PDF form. You can view the form using Internet Explorer. If you are using another browser, you can download the file and view it in Adobe Reader.
• Vaccine Information Sheet for School Immunization
• COVID-19 Vaccine Information Sheet – Children ages 6 months to under 5 years

Provincial Guidance

• Chief Medical Officer of Health Memo: COVID-19 Vaccine Program Update – October 21, 2022 *new*
• Chief Medical Officer of Health Memo: COVID-19 Vaccine Booster Program Update – July 13, 2022
• Chief Medical Officer of Health Memo: COVID-19 Vaccine Update for Ages 5 to 11 – June 29, 2022
• Clinic Guidance for COVID-19 Immunization
• Chief Medical Officer of Health Memo: Information for Physicians and Nurse Practitioners related to COVID-19 Vaccine
• Chief Medical Officer of Health Memo: COVID-19 Vaccine Update – November 25, 2021
• Chief Medical Officer of Health Memo: COVID-19 Booster Doses for Immunocompromised – January 13, 2022
• Guidance Document on the Management of COVID-19 Vaccine Errors
• NL Guidance: COVID-19 Vaccine Shipping and Receiving
• Special Populations for COVID-19 Vaccination
• Medical Directive Administration of COVID-19 Vaccine
• COVID-19 Vaccine Booster Dose Program – November 9, 2021

Infection Prevention and Control

• Best Ways to Prevent COVID-19
• Donning and doffing instructions: PPE Used for Droplet and Contact Precautions

Health Canada

• Regulatory Statement on AstraZeneca

National Advisory Committee on Immunization (NACI)

• COVID-19: Preliminary guidance on key populations for early COVID-19 immunization
• Guidance on the prioritization of initial doses of COVID-19 vaccine(s)
• NACI rapid response: Extended dose intervals for COVID-19 vaccines to optimize early vaccine rollout and population protection in Canada
• NACI rapid response: Interchangeability of authorized COVID-19 vaccines
• Recommendations on the use of COVID-19 vaccine(s)
• Recommended use of AstraZeneca COVID-19 vaccine in younger adults
• Webinar: Recommendations on the use of the Pfizer-BioNTech COVID-19 Vaccine
• Recommendation on the use of mRNA COVID-19 vaccines in adolescents 12 to 17 years of age
• NACI rapid response: Additional dose of COVID-19 vaccine in immunocompromised individuals following 1- or 2- dose primary series

 Public Health Agency of Canada

• Canada’s COVID-19 Immunization Plan: Saving Lives and Livelihoods
• Planning Guidance for Administration of COVID-19 Vaccine
• Planning Guidance for Immunization Clinics for COVID-19 Vaccines
• Statement from the Council of Chief Medical Officers of Health on use of AstraZeneca COVID-19 vaccine in younger adults
• Vaccines and Treatments for COVID-19
• Webinar: COVID-19 Vaccine Foundations for Health Care Providers

Vaccine Product Information 

• AstraZeneca COVID-19 Vaccine Product Monograph
• Additional Information for AstraZeneca Vaccine Consent Process
• COVISHIELD COVID-19 Vaccine Product Monograph
• Janssen COVID-19 Vaccine Product Monograph
• Moderna COVID-19 Vaccine Product Monograph
• Pfizer-BioNTech COVID-19 Vaccine Product Monograph
• Pfizer Information about Low Dead-Volume Syringes and/or Needles
• Pfizer Canada
• Pfizer-BioNTech COVID-19 Vaccine
• Pfizer-BioNTech Vaccination Storage and Dry Ice Safety Handling

Pharmacist Guidance

• Chief Medical Officer of Health Memo: COVID-19 Vaccine Booster Program Update – July 13, 2022 *new*
• Memo from the CMOH to Pharmacists and Physicians on COVID-19 Booster Doses – April 13, 2022
• Memo from the Chief Medical Officer of Health – COVID-19 Booster Doses for Immunocompromised – January 13, 2022
• Memo from the Chief Medical Officer of Health – COVID-19 Vaccine Update – November 25, 2021
• Memo from the Chief Medical Officer of Health – Offer Booster Doses of COVID-19 Vaccine
• Memo from the Chief Medical Officer of Health – Guidance for Offering the Same COVID-19 Vaccine Product and Offering Additional Dose of COVID-19 Vaccine for Moderately to Severely Immunocompromised Individuals
• Memo from the Chief Medical Officer of Health – COVID-19 Vaccine Interval Update
• After Care and Immunization Record
• All Adverse Events Following Immunization (AEFIs) are to be reported to the Regional Medical Officer of Health. For details, please refer to the Newfoundland and Labrador Immunization Manual.
  • Report of AEFI Form
• Clinic Guidance for COVID-19 Immunization
• Vaccine Storage and Handling Factsheet for Pharmacists
• Vaccine Information Sheet
• Newfoundland and Labrador COVID-19 Immunization Program Presentation
• HEALTHe NL and COVID-19 Vaccinations
• Quick Reference Guide – HEALTHe NL Immunizations Tab
• Vaccine Order Form

Physician Guidance

• Chief Medical Officer of Health Memo: COVID-19 Vaccine Booster Program Update – July 13, 2022 *new*
• Memo from the CMOH to Pharmacists and Physicians on COVID-19 Booster Doses – April 13, 2022
• Memo from the Chief Medical Officer of Health – COVID-19 Booster Doses for Immunocompromised – January 13, 2022
• Memo from the Chief Medical Officer of Health – COVID-19 Vaccine Update – November 25, 2021
• Memo from the Chief Medical Officer of Health – Offer Booster Doses of COVID-19 Vaccine
• Memo from the Chief Medical Officer of Health – Guidance for Offering the Same COVID-19 Vaccine Product and Offering Additional Dose of COVID-19 Vaccine for Moderately to Severely Immunocompromised Individuals
• Memo from the Chief Medical Officer of Health – COVID-19 Vaccine Interval Update
• Memo for Community-Based Physicians Offering COVID-19 Vaccine
• MCP Newsletter: Temporary COVID-19 Immunization Fee Codes
• MCP Newsletter: COVID-19 Immunization Documentation Requirements for Physicians unable to use Med Access
• After Care and Immunization Record
• All Adverse Events Following Immunization (AEFIs) are to be reported to the Regional Medical Officer of Health. For details, please refer to the Newfoundland and Labrador Immunization Manual.
  • Report of AEFI Form
• Clinic Guidance for COVID-19 Immunization
• Vaccine Information Sheet
• HEALTHe NL and COVID-19 Vaccinations for EMR Users
• Quick Reference Guide – HEALTHe NL Immunizations Tab via EMR
• Vaccine Order Form